Market Intelligence, Clinical Progress, and High-Purity Reagents for Endocrine-Driven Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CYP19A1 (Aromatase) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CYP19A1 Recombinant Protein / Mutant Panel High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Full-length or truncated variants available. Ideal for PROTAC binding assays. |
View CYP19A1 Products |
| Gene Delivery | CYP19A1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Essential for native intracellular membrane conformation. Ideal for steroidogenic activity assays. |
View CYP19A1 Products |
| Benchmark Ab | Anti-CYP19A1 Recombinant Antibody (Sequence Verified) Recombinant positive control for expression validation, western blot, and target engagement assays. |
View CYP19A1 Products |
| Validator | CYP19A1 siRNA Set For knockdown verification and off-target screening in cell-based inhibition studies. |
View CYP19A1 Products |
| Related Target: ESR1 | ESR1 Downstream estrogen receptor; critical for resistance bypass and combination strategy. Acquired ESR1 mutations drive resistance to CYP19A1 inhibition. |
View ESR1 Products |
| Related Target: CYP17A1 | CYP17A1 Upstream steroidogenic enzyme; off-target liability counter-screening and combination hormone suppression. |
View CYP17A1 Products |
| Related Target: CDK4 | CDK4 Key synergistic node. Dual blockade of CYP19A1 and CDK4/6 is standard of care for ER+ breast cancer. |
View CDK4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Off-target CYP selectivity (CYP11B1, CYP17A1, CYP21A2) | Ortholog and paralog panel proteins strictly verified by mass spec; Human/Mouse/Cyno CYP19A1 available with >95% purity |
| Drug resistance mutation profiling | Mutant recombinant library (e.g., polymorphic variants) for next-gen inhibitor counter-screening |
| Intracellular Membrane Localization | Lentivirus and Promise-ORF vectors available for native stable cell line construction |
| Lack of Controls | Clinical Benchmark reference inhibitors (e.g., Letrozole/Anastrozole class standards) and Biosimilar-grade antibodies included |
| False Positives / Assay interference | Validated siRNA included for target-specificity confirmation in cellular aromatase activity assays |
Live CYP19A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CYP19A1 therapeutics is shifting toward next-generation selective inhibitors and bifunctional degraders. As first-generation non-steroidal aromatase inhibitors face generic competition and acquired resistance, the next wave of R&D is targeting mutant-selective profiles and combination regimens with ESR1 antagonists. While third-generation AIs remain the backbone of ER+/HER2- breast cancer treatment, resistance driven by estrogen-independent signaling and ESR1 mutations presents a major clinical hurdle. The next wave of R&D is intensely targeting aromatase degraders (PROTACs) and rationally designed small molecules to overcome acquired resistance, minimize off-target steroidal side effects, and optimize combination therapies with CDK4/6 and PI3K/AKT pathway inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Next-Gen Small Molecule Inhibitors | Novartis, Eli Lilly, Pfizer, AstraZeneca, local generics | HR+ Breast Cancer, Endometriosis | Selectivity Assay (Need Mutant vs WT Proteins + paralog panel) |
| PROTAC / Degrader | Arvinas, Kymera (Early Stage); Preclinical academic/industry labs | Refractory HR+ Breast Cancer | Cellular degradation assay (Need high-purity protein for pulldown/SPR) |
| Combination Endocrine Therapy | Daiichi Sankyo, AstraZeneca, Eli Lilly, Novartis | Metastatic HR+ / HER2- Breast Cancer | Dual-target inhibition validation (Need CYP19A1 + ESR1 co-assay reagents) |
| Biosimilar / Biobetter mAb (adjunct IHC) | Diagnostic partners | Companion Diagnostics | High-specificity Anti-CYP19A1 antibody controls |
Key Mutations and Polymorphisms
Key mutations and polymorphisms in CYP19A1 include:
- rs2236722 (Arg264Cys): Associated with reduced aromatase activity and altered drug response.
- rs28757184: A missense variant with potential functional impact.
- Val80Leu: A polymorphism linked to changes in enzyme kinetics and inhibitor sensitivity.
- rs4646, rs10046: Polymorphisms associated with breast cancer risk and treatment outcomes.
Assay Strategy Recommendations
- Recombinant Enzyme Inhibition Assay: Use HEK293-expressed CYP19A1 recombinant protein (>95% purity, Sequence Verified) with exogenous POR and cytochrome b5 to reconstitute enzyme activity. Detect inhibition using radiolabeled (e.g., [1β-3H]androstenedione) or fluorescent substrates.
- Selectivity Counter-Screening: Build a panel of homologous proteins (CYP11B1, CYP17A1, CYP21A2) to compare IC50 shifts and ensure family selectivity.
- Cell-Based Functional Validation: Use CYP19A1 Lentivirus to construct stable overexpression cell lines, combined with LC-MS/MS quantification of estradiol production, to confirm compound cell permeability and true target efficacy.
- Resistance Mutation Analysis: Use CYP19A1 mutant recombinant proteins (e.g., Val80Leu, Arg264Cys) to assess lead molecule inhibition sensitivity across different genotypes and predict clinical resistance risk.
- Target Confirmation: Use CYP19A1 siRNA for knockdown to confirm on-target activity at the cellular level and eliminate assay false positives.